Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00481052
Status:
COMPLETED
Last Update Posted:
2022-01-18
First Post:
2007-05-31
Brief Title:
Nilotinib as First-line Treatment of Ph CML in Early Chronic Phase
Sponsor:
Gruppo Italiano Malattie EMatologiche dellAdulto
Organization:
Gruppo Italiano Malattie EMatologiche dellAdulto
Organization Data
Organization:
Gruppo Italiano Malattie EMatologiche dellAdulto
Class:
OTHER
Study ID:
CML0307
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dellAdulto
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None